Replimune Group, Inc. filings document regulatory, financing, governance and operating disclosures for a Nasdaq-listed clinical-stage biotechnology company focused on oncolytic immunotherapies. Recent Form 8-K reports cover FDA communications involving the RP1 Biologics License Application, including complete response letters and related Regulation FD disclosures.
The filing record also documents quarterly financial results, corporate presentation materials for RP1 and RP2 programs, amendments to the company’s loan and security agreement, and annual meeting voting results. These disclosures describe Replimune’s development-stage operating profile, capital structure arrangements, stockholder governance matters and material events tied to its cancer immunotherapy pipeline.
Replimune Group, Inc. director and Chief Executive Officer Sushil Patel reported a sale of 39,341 shares of common stock on 2026-08-10 at $12.97 per share. According to the disclosure, these shares were sold to cover tax withholding obligations arising from the vesting of performance-based restricted stock units under an irrevocable "sell to cover" provision and do not represent a discretionary sale. Following this transaction, Patel directly holds 708,151 shares of Replimune common stock.
Replimune Group, Inc. Chief Financial Officer Emily Luisa Hill reported a sale of 11,448 shares of common stock on 2026-08-10 at $12.97 per share. According to the disclosure, the shares were sold to cover tax withholding obligations upon vesting of performance-based RSUs and were executed under an irrevocable “sell to cover” provision, leaving her with 225,108 shares held directly.
Replimune Group, Inc. Chief Medical Officer Konstantinos Xynos reported a sale of 11,447 shares of common stock on 2026-08-10 at $12.97 per share. According to the disclosure, the shares were sold to cover tax withholding obligations upon vesting of performance-based RSUs under an irrevocable "sell to cover" provision and were not a discretionary sale. Following this transaction, Xynos directly holds 224,215 shares of Replimune common stock.
Replimune Group, Inc. Chief Accounting Officer Andrew Schwendenman reported a sale of 7,632 shares of common stock on 2026-08-10 at $12.97 per share. According to the company disclosure, the shares were sold solely to cover tax withholding obligations arising from the vesting of performance-based restricted stock units under an irrevocable “sell to cover” provision, and were not a discretionary sale. Following the transaction, Schwendenman directly holds 99,425 shares of Replimune common stock.
Baker Bros. Advisors and related entities filed an amended beneficial ownership report on Replimune Group, Inc. common stock. The group reports beneficial ownership of 11,075,336 shares, representing 11.8% of Replimune’s common stock, based on an outstanding share count that includes a recent equity offering and certain vested options.
On August 9, 2026, Replimune entered into an underwriting agreement with Leerink Partners, J.P. Morgan Securities, and Cantor Fitzgerald for a public offering of 9,701,490 shares of common stock at $12.06 per share and 2,736,340 pre-funded warrants at $12.0599 per warrant, all exercisable 1-for-1 into common stock at an exercise price of $0.0001 with no expiration. The offering closed on August 11, 2026.
Funds advised by Baker Bros. purchased all 2,736,340 2026 $0.0001 pre-funded warrants for an aggregate $32,999,986.77, using working capital. Existing $0.0001 and $0.001 pre-funded warrants are subject to 4.99% and 9.99% beneficial ownership caps, respectively, so these warrants are not currently exercisable due to those limits. Director Michael Goller holds stock options and is subject to a lock-up through September 24, 2026, in his individual capacity.
Replimune Group, Inc. reported that investment funds advised by Baker Bros. Advisors LP purchased a total of 2,736,340 "2026 $0.0001 Prefunded Warrants" in an underwritten public offering that closed on August 11, 2026, at $12.0599 per warrant. Each warrant is exercisable immediately on a 1-for-1 basis into Common Stock at an exercise price of $0.0001 per share, subject to a 4.99% beneficial ownership cap, which the funds may adjust up to 19.99% effective 61 days after written notice. The Baker entities and individuals disclaim beneficial ownership beyond their pecuniary interest.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC report beneficial ownership of 4,418,837.86 shares of Replimune Group Inc. common stock, representing 5.3% of the class. All voting and dispositive authority is reported as shared, with no sole voting or dispositive power.
The position is held through Goldman Sachs & Co. LLC, a broker-dealer and registered investment adviser and a subsidiary of The Goldman Sachs Group, Inc. The reporting units within Goldman Sachs disclaim beneficial ownership for certain client accounts and investment entities where third parties hold economic interests.
Replimune Group, Inc. describes an underwritten offering of 9,701,490 shares of common stock and pre-funded warrants to purchase 2,736,340 shares, and amends prior disclosure to correct the initial beneficial ownership limits on those warrants. The shares are priced at $12.06 each and the pre-funded warrants at $12.0599, reflecting a $0.0001 exercise price.
The pre-funded warrants are exercisable after issuance but include a 4.99% beneficial ownership cap, adjustable up to 19.99% with 61 days prior notice. Replimune estimates $140.5 million in net proceeds from the offering, conducted with Leerink Partners, J.P. Morgan Securities, and Cantor Fitzgerald under an effective Form S-3 shelf registration.
Replimune Group, Inc. entered into an underwriting agreement with Leerink Partners, J.P. Morgan and Cantor Fitzgerald for a primary underwritten offering of its equity. The company is issuing 9,701,490 shares of common stock and pre-funded warrants to purchase 2,736,340 shares of common stock.
The common shares are priced at $12.06 per share, and the pre-funded warrants at $12.0599 each, reflecting a $0.0001 per share exercise price on the warrants. Replimune expects gross proceeds of approximately $150 million and estimates net proceeds of approximately $140.5 million after underwriting discounts, commissions and expenses. The offering, made under an existing Form S-3 shelf registration statement, is expected to close on or about August 11, 2026, subject to customary conditions.
The pre-funded warrants are exercisable at any time after issuance, subject to a 9.99% beneficial ownership cap, which holders can adjust (up to 9.99%) with 61 days’ prior notice. All securities in the offering are being sold by Replimune.
Replimune Group is conducting a primary offering of 9,701,490 shares of common stock and pre-funded warrants to purchase 2,736,340 shares, at $12.06 per share and $12.0599 per pre-funded warrant, for gross proceeds of about $150.0 million. After underwriting fees and expenses, Replimune expects net proceeds of approximately $140.5 million, to fund the commercial launch of its oncolytic immunotherapy TUDRIQEV, expansion of the RPx platform (including further RP2 development), and general corporate purposes. Shares outstanding will rise to 92,418,413, excluding new warrant exercises. TUDRIQEV recently received FDA accelerated approval in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed on anti‑PD‑1 therapy; continued approval depends on confirmatory trials, notably the ongoing IGNYTE‑3 Phase 3 study. The company reports substantial net losses, an accumulated deficit and going‑concern doubt, and states it will require additional capital beyond this raise.